Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain Therapeutics Inc. is based in BETHESDA, Md.
| Revenue (Most Recent Fiscal Year) | $0.05M |
| Net Income (Most Recent Fiscal Year) | $-20.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -222.61% |
| Return on Assets (Trailing 12 Months) | -135.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.89 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 29.43M |
| Free Float | 27.31M |
| Market Capitalization | $57.09M |
| Average Volume (Last 20 Days) | 0.29M |
| Beta (Past 60 Months) | 0.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.18% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.97% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |